Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Chandrika Jeyamohan"'
Autor:
Levi Sokol, Kim M. Hirshfield, Chandrika Jeyamohan, Srilatha Simhadri, Janice M. Mehnert, Lorna Rodriguez-Rodriguez, Husam Al-Hraishawi, Shridar Ganesan, Sharon R. Pine, Atul Kulkarni, Suzie Chen, Man Lung Teo, Eileen White, Siraj M. Ali
Publikováno v:
Clinical Cancer Research. 23:5631-5638
Purpose: Many patients with BRAFV600E mutant melanoma treated with BRAF inhibitors experience a rapid response, but ultimately develop resistance. Insight into the mechanism of resistance is critical for development of more effective treatment strate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f956d962a01753d2ef8618d2f2f582d3
https://doi.org/10.1158/1078-0432.ccr-16-0758
https://doi.org/10.1158/1078-0432.ccr-16-0758
Autor:
Alexandre Lambert, Dimitrios Zardavas, Chandrika Jeyamohan, Maxwell V. Meng, Toshiki Maeda, Neal D. Shore, Gary D. Steinberg, Li Zhu, Bruce S. Fischer, Fred Witjes, Noah M. Hahn, Badrinath R. Konety, Sam S. Chang, John A. Taylor, Joan Palou, Hiroyuki Nishiyama, Bradley Raybold, Juergen E. Gschwend
Publikováno v:
Journal of Clinical Oncology. 38:TPS5090-TPS5090
TPS5090 Background: Immune checkpoint inhibitors, including NIVO (anti–PD-1), have demonstrated favorable tolerability and efficacy profiles, ushering in a new treatment (tx) paradigm for advanced bladder cancer (advBC). However, an unmet need exis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2c0434776e6814443142de9bc5eae8d
https://doi.org/10.1200/jco.2020.38.15_suppl.tps5090
https://doi.org/10.1200/jco.2020.38.15_suppl.tps5090
Autor:
Eileen White, Murugesan Gounder, Robert S. DiPaola, Hongxia Lin, Simantini Eddy, Susan Goodin, Kevin Bray, M. N. Stein, Chandrika Jeyamohan, Dmitri Dvorzhinski
Publikováno v:
The Prostate. 70:1388-1394
A profound difference between cancer and normal tissues is the preferential utilization of glycolysis by cancer cells. To translate this paradigm in the clinic, we completed a phase I study of 2-deoxyglucose (2DG), and assessed 2DG uptake with fluoro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c5b7d4dc131dd7a909e0da298c30b07
https://doi.org/10.1002/pros.21172
https://doi.org/10.1002/pros.21172
Autor:
Howard L. Kaufman, Mark N. Stein, Walter M. Stadler, Maha Hussain, Irina V. Tereshchenko, Robert S. DiPaola, Chandrika Jeyamohan, Glenn Liu, Susan Goodin, Janice M. Mehnert
In a phase II multicenter study, men with castration sensitive metastatic prostate cancer were treated with AT-101, a small molecule Bcl-2 inhibitor, and androgen deprivation therapy. At the end of 7 cycles of therapy in 55 patients, an undetectable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f919f59f3161c405dee659372a462280
https://europepmc.org/articles/PMC4698193/
https://europepmc.org/articles/PMC4698193/
Autor:
Tina M. Mayer, Eileen White, Dirk F. Moore, Chunxia Chen, Robert S. DiPaola, Mridula George, Mark N. Stein, Chandrika Jeyamohan
Publikováno v:
Journal of Clinical Oncology. 35:102-102
102 Background: For patients who have a rising prostate-specific antigen value after definitive local therapy, androgen deprivation is a commonly employed option. However, immediate hormonal therapy has not been shown to alter the progression of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4ed364c7f9fd108cb80c7f519a8ed32
https://doi.org/10.1200/jco.2017.35.6_suppl.102
https://doi.org/10.1200/jco.2017.35.6_suppl.102
Autor:
Roger K. Strair, Lien Huzzy, Chandrika Jeyamohan, Robert S. DiPaola, Mark N. Stein, Tina M. Mayer, Monica Anand, Mecide Gharibo
Publikováno v:
Journal of Clinical Oncology. 31:464-464
464 Background: Treatment of patients with RCC using IAL from a haploidentical donor (sibling/parent), without prior conditioning of the recipient, induced tumor regressions in 3/13 patients with minimal toxicity (Strair J Clin Onc 2003:3785). Respon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8e9e2db6397d8946964d0a973e358e8
https://doi.org/10.1200/jco.2013.31.6_suppl.464
https://doi.org/10.1200/jco.2013.31.6_suppl.464
Autor:
Monica Anand, S. Percy Ivy, Chandrika Jeyamohan, D. Metzger, Mark N. Stein, Tina M. Mayer, Robert S. DiPaola
Publikováno v:
Journal of Clinical Oncology. 30:219-219
219 Background: Notch signaling is a key determinant of cell fate. RO492 is a selective γ-secretase inhibitor blocking cleavage of Notch. We hypothesize that anti-androgen therapy will lead to an enriched population of basal prostate cancer stem cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ce46a155302b8cc05c7313700febf42
https://doi.org/10.1200/jco.2012.30.5_suppl.219
https://doi.org/10.1200/jco.2012.30.5_suppl.219
Autor:
Xi Zheng, Monica Anand, Elisabeth I. Heath, Weichung Shih, Mark N. Stein, Chandrika Jeyamohan, Robert S. DiPaola, Susan Goodin, Shou-En Lu, Robert A. Somer, Tina M. Mayer, Allan H. Conney
Publikováno v:
Journal of Clinical Oncology. 30:89-89
89 Background: Single agent atorvastatin and celecoxib have been associated with reductions in the risk of PC. Our laboratories have demonstrated that low doses of the drug combination have synergistic effects inhibiting the progression of LNCaP tumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::750a9e2c41a5329161f9a4c5d546a05e
https://doi.org/10.1200/jco.2012.30.5_suppl.89
https://doi.org/10.1200/jco.2012.30.5_suppl.89
Autor:
Maha Hussain, Chandrika Jeyamohan, Greg Wilding, Simantini Eddy, M. N. Stein, Walter M. Stadler, I. Khan, Glenn Liu, Robert S. DiPaola, Edwin M. Posadas
Publikováno v:
Journal of Clinical Oncology. 29:137-137
137 Background: Preclinical studies demonstrate that Bcl-2 is over-expressed in most pts with prostate cancer, causes drug resistance to ADT, and that modulation of Bcl-2 improves sensitivity of tumor cells. We are conducting a phase II study for men
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed703790e4cb5dfded7392c8ee7f4b58
https://doi.org/10.1200/jco.2011.29.7_suppl.137
https://doi.org/10.1200/jco.2011.29.7_suppl.137
Autor:
Eileen White, T. McCarthy, Dirk F. Moore, Monika Anand, Chandrika Jeyamohan, Robert S. DiPaola, Tina M. Mayer, F. Collins, M. N. Stein, D. Metzger
Publikováno v:
Journal of Clinical Oncology. 29:164-164
164 Background: Autophagy is conserved, genetically controlled catabolic response to starvation and stress whereby cells self- digest intracellular proteins and organelles by targeting them for degradation in lysosomes to generate energy and mitigate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce7189861123b9bcc8be6a6b50451c33
https://doi.org/10.1200/jco.2011.29.7_suppl.164
https://doi.org/10.1200/jco.2011.29.7_suppl.164